Diagnostic and prognostic contribution of targeted NGS in patients with triple-negative myeloproliferative neoplasms

Am J Hematol. 2019 Oct;94(10):E264-E267. doi: 10.1002/ajh.25580. Epub 2019 Aug 6.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • DNA (Cytosine-5-)-Methyltransferases / genetics
  • DNA / genetics*
  • DNA Methyltransferase 3A
  • DNA Mutational Analysis / methods*
  • DNA-Binding Proteins / genetics
  • Dioxygenases
  • Exons / genetics
  • Female
  • High-Throughput Nucleotide Sequencing*
  • Humans
  • Male
  • Middle Aged
  • Phosphoproteins / genetics
  • Primary Myelofibrosis / diagnosis
  • Primary Myelofibrosis / genetics*
  • Primary Myelofibrosis / mortality
  • Prognosis
  • Proto-Oncogene Proteins / genetics
  • RNA Splicing Factors / genetics
  • Receptors, Thrombopoietin / genetics*
  • Thrombocythemia, Essential / diagnosis
  • Thrombocythemia, Essential / genetics*
  • Thrombocythemia, Essential / mortality

Substances

  • DNA-Binding Proteins
  • DNMT3A protein, human
  • Phosphoproteins
  • Proto-Oncogene Proteins
  • RNA Splicing Factors
  • Receptors, Thrombopoietin
  • SF3B1 protein, human
  • MPL protein, human
  • DNA
  • Dioxygenases
  • TET2 protein, human
  • DNA (Cytosine-5-)-Methyltransferases
  • DNA Methyltransferase 3A